Zenas BioPharma, Inc. (ZBIO) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−4.1x

Market Cap

$2.14B

MomentumView details →

1D Return

−0.12%

YTD Return

−9.47%

RSI (14)

56.4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−4.1x

Market Cap

$2.14B

RSI (14)

56.4

MomentumView details →

1D Return

−0.12%

YTD Return

−9.47%

SummaryUpdated Jun 1, 2026

Zenas BioPharma, Inc. (NASDAQ:ZBIO) is a clinical-stage biopharmaceutical company founded in 2019 and headquartered in Waltham, Massachusetts. The company went public in September 2024 through an initial public offering. Zenas focuses on developing transformative immunology-based therapies for autoimmune and inflammatory diseases, with its lead product candidate obexelimab currently in clinical trials for multiple indications including rare autoimmune conditions and multiple sclerosis.

Ask drillr about Zenas BioPharma, Inc. →

ProfitabilityView details →

Gross Margin

−5972.60%

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−196.03%

ROA (TTM)

−69.03%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

−93.33%

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

−55.28%

EPS CAGR 3Y

—

EBITDA YoY

—

EarningsView details →

EPS (Actual)

−$1.77

EPS Surprise

−58.04%

Beats (12Q)

1/12

Next Q EPS Est

−$1.22

Avg Surprise (4Q)

−114.55%

Rev Surprise

−93.33%

Capital & dividendView details →

Debt/Equity

1.58x

Current Ratio

9.93x

Quick Ratio

9.93x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

1.00M

Net Income (TTM)

−484.38M

Op. CF (TTM)

−225.97M

Next earningsNov 12, 2026 →

Latest newsMore news →

Zenas BioPharma's CFO will transition to Strategic Advisor to the Board Chair at the end of September.23d ago

Zenas BioPharma expanded its Board of Directors with the appointment of Christy Oliger, who brings more than 30 years of global biopharmaceutical commercial and operating experience.23d ago

Similar companies

Aurinia Pharmaceuticals Inc.AUPH Shandong Boan Biotechnology Co., Ltd.06955.HK ADMA Biologics, Inc.ADMA UroGen Pharma Ltd.URGN Rapport Therapeutics, Inc. Common StockRAPP PegBio Co., Ltd.02565.HK Find similar companies →

Latest newsMore news →

Zenas BioPharma's CFO will transition to Strategic Advisor to the Board Chair at the end of September.23d ago Zenas BioPharma expanded its Board of Directors with the appointment of Christy Oliger, who brings more than 30 years of global biopharmaceutical commercial and operating experience.23d ago